
BioIncept, a New Jersey-based biotech firm, innovates compounds for human embryo development.
BioIncept, founded in Cherry Hill, New Jersey, is a pioneering biotechnology company dedicated to advancing human embryo development. The company's core mission is to enhance reproductive health through innovative compounds that promote implantation and trophoblast invasion. BioIncept's vision encompasses a broader application of its proprietary platform in regenerative medicine and cellular repair, aiming to deliver life-saving therapeutics globally.
Notable figures affiliated with BioIncept include leading researchers and scientists in the field of developmental biology. The company has established a global research network, contributing significantly to advancements in reproductive health and tissue regeneration. BioIncept's key achievements include the development of groundbreaking compounds that have the potential to revolutionize fertility treatments and regenerative medicine, marking a significant impact on both medical science and patient care.

Incept BioSystems

Granata Bio
granata.bio

INVO Fertility
invobioscience.com

Bioceptive
bioceptive.com

Ventrinova

Inceptor Bio
inceptor.bio

Endogena Therapeutics

Intrance Medical Systems

BioRegenx
bioregenx.com

Regenemed
regenemed.com

Inception Sciences

Spheringenics

InGeneron
ingeneron.com

Histogen
histogen.com

BioTissue
biotissue.com
Companies similar to Bioincept include Incept BioSystems, Granata Bio, INVO Fertility and Bioceptive.
Bioincept was founded in 1996.
Bioincept's headquarters is located in New York City, NY, US.
Bioincept's most recent funding round was for $3.1M (USD) in October 2020.
As of Oct 19, 2020, Bioincept has raised a total of $15.6M (USD).
Bioincept has 9 employees as of Feb 5, 2024.